Omi/HtrA2在腺样囊性癌的表达及其临床意义

Omi/HtrA2 Epression and Clinical Significance of Adenoid Cystic Carcinoma

目的探讨Omi/Htr A2在不同分型腺样囊性癌中的表达差异,并评价其对腺样囊性癌的临床意义。方法纳入确诊为腺样囊性癌的患者100例,应用免疫组织化学染色方法,检测Omi/Htr A2在不同分型腺样囊性癌中的表达;并检测腺样囊性癌转移组和非转移组患者中Omi/Htr A2表达情况。结果 Omi/Htr A2表达主要位于细胞胞质中,在腺样囊性癌组织中其阳性率为83%;腺样囊性癌低级组与高级组间表达情况具有统计学差异(P<0.05),但不同分型的腺样囊性癌组织中其表达差异无统计学意义(P>0.05);Omi/Htr A2在转移组腺样囊性癌中阳性率为93.1%,在非转移组中其阳性率为46.2%,两组比较具有统计学差异(P<0.05)。结论 Omi/Htr A2与腺样囊性癌的发病密切相关,可作为临床判断腺样囊性癌的辅助性指标,对临床的诊治及预后的判断具有一定的指导价值。

Objective To investigate the expression of Omi/HtrA2 in different subtypes of adenoid cystic carcinoma and to evaluate its clinical significance for adenoid cystic carcinoma. Methods 100 cases of patients diagnosed with adenoid cystic carcinoma were enrolled. The expression of Omi/HtrA2 in different subtypes of adenoid cystic carcinoma was detected by immunohistochemical staining. The expression of Omi/HtrA2 in adenoid cystic carcinoma and non-metastatic group were detected. Results The expression of Omi/HtrA2 was mainly located in cytoplasm and 83% in adenoid cystic carcinoma. The expression of Omi/ HtrA2 was statistically different （ P 〈 0.05 ） （ P 〉 0.05 ）. The positive rate of Omi/HtrA2 in the adenoid cystic carcinoma was 93.1% in the non-metastatic group, but the difference was not statistically significant （ P 〉 0.05 ）. The positive rate was 46.2%, the 2 groups were statistically significant （ P 〈 0.05 ）. Conclusion Omi/HtrA2 incidence of adenoid cystic carcinoma is closely related to clinical judgment as adenoid cystic carcinoma auxiliary index, has a guiding value for diagnosis and clinical prognosis.